Article Versions Notes

Keegan NM, Furney SJ, Walshe JM, Gullo G, Kennedy MJ, Smith D, McCaffrey J, Kelly CM, Egan K, Kerr J, et al. Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”. Cancers. 2021; 13(6):1225. https://doi.org/10.3390/cancers13061225

Keegan, Niamh M., Simon J. Furney, Janice M. Walshe, Giuseppe Gullo, M. John Kennedy, Diarmuid Smith, John McCaffrey, Catherine M. Kelly, Keith Egan, Jennifer Kerr, and et al. 2021. "Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”" Cancers 13, no. 6: 1225. https://doi.org/10.3390/cancers13061225

Keegan, N. M., Furney, S. J., Walshe, J. M., Gullo, G., Kennedy, M. J., Smith, D., McCaffrey, J., Kelly, C. M., Egan, K., Kerr, J., Given, M., O’Donovan, P., Hernando, A., Teiserskiene, A., Parker, I., Kay, E., Farrelly, A., Carr, A., Calzaferri, G., ... Hennessy, B. T. (2021). Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”. Cancers, 13(6), 1225. https://doi.org/10.3390/cancers13061225